A Phase 1/2 interventional study of Placebo and TRC101 in Acidosis, sponsored by Tricida, Inc.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-01-14.
Sponsored by Tricida, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a double-blind, placebo-controlled, parallel-design, 6-arm, fixed dose study. The study enrolled 135 adult male and female subjects with Stage 3 or 4 chronic kidney disease and low serum bicarbonate levels. The study was conducted in two parts. In Part 1 study drug dosing (TRC101 or placebo) continued for 14 days twice daily (BID). In Part 2 study drug dosing (TRC101 or placebo) continued for 14 days once daily (QD).
The maximum study duration per subject was anticipated to be up to 42 days.
111 studies on the registry are indexed under Acidosis; 19 are open to participants now.
This study's enrollment of 135 is above the median of 52 across 79 interventional studies indexed under Acidosis.
Browse Acidosis studies →Tricida, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered twice daily (BID) for 14 days
Drug: Placebo
Administered twice daily (BID) for 14 days
Drug: TRC101
Administered twice daily (BID) for 14 days
Drug: TRC101
Administered twice daily (BID) for 14 days
Drug: TRC101
Administered once daily (QD) for 14 days
Drug: TRC101
Administered once daily (QD) for 14 days
Drug: Placebo
oral suspension
oral suspension
Also known as: Veverimer
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE
The number and percentage of subjects who reported treatment-emergent adverse events (TEAEs) summarized by system organ class and preferred term (see Reported Adverse Events) as well as by severity, causality, seriousness, and action taken with regard to study drug. All analyses were descriptive.
Time frame: Through treatment period completion (Day 15)
Change From Baseline to the End of Treatment (Day 15) in Serum Bicarbonate Within Each Individual TRC101 Dose Group
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline
Time frame: Baseline and Day 15
Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between Each TRC101 Dose Group Versus Placebo
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for each TRC101 dose group versus that for Placebo
Time frame: Baseline and Day 15
Change From Baseline in Serum Bicarbonate at Day 15 Within the Combined TRC101 Treatment Group
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline
Time frame: Baseline and Day 15
Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between the Combined TRC101 Treatment Group Versus Placebo
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the Combined TRC101 Treatment Group versus that for Placebo
Time frame: Baseline and Day 15
Comparison of the Proportion of Subjects Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Between Each TRC101 Dose Group Versus Placebo
Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between each TRC101 BID Dose Group versus Placebo
Time frame: Baseline and Day 15
Change From Baseline in Serum Bicarbonate at Day 15 Within the TRC101 6g QD Dose Group
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline
Time frame: Baseline and Day 15
Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus Placebo
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g dose group versus that for Placebo
Time frame: Baseline and Day 15
Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus the TRC101 3g BID Dose Group
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g QD dose group versus that for the TRC101 3g BID dose group
Time frame: Baseline and Day 15
Comparison of the Proportion of Subjects in the TRC101 6g QD Dose Group Whose Serum Bicarbonate Values Increased From Baseline to Day 15 by Greater Than or Equal to 2, 3, or 4 mEq/L Versus Placebo
Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between the 6g TRC101 QD Dose Group versus Placebo
Time frame: Baseline and Day 15
| Milestone | Placebo BID | 1.5g TRC101 BID | 3g TRC101 BID | 4.5g TRC101 BID | Placebo QD | 6g TRC101 QD |
|---|---|---|---|---|---|---|
| Started | 25 | 25 | 25 | 26 | 6 | 28 |
| Completed | 25 | 25 | 25 | 26 | 6 | 28 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
The number and percentage of subjects who reported treatment-emergent adverse events (TEAEs) summarized by system organ class and preferred term (see Reported Adverse Events) as well as by severity, causality, seriousness, and action taken with regard to study drug. All analyses were descriptive.
| Participants | Pooled Placebo | 1.5g TRC101 BID | 3g TRC101 BID | 4.5g TRC101 BID | 6g TRC101 QD |
|---|---|---|---|---|---|
| Subjects Reporting any TEAE | 14 | 13 | 9 | 17 | 17 |
| ≥ 1 Mild TEAE | 11 | 9 | 8 | 14 | 15 |
| ≥ 1 Moderate TEAE | 3 | 4 | 1 | 3 | 2 |
| ≥ 1 Severe TEAE | 0 | 0 | 0 | 0 | 0 |
| ≥ 1 Serious TEAE | 0 | 0 | 0 | 0 | 0 |
| Study Drug Discontinuation Due to TEAE | 0 | 0 | 0 | 0 | 0 |
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline
| mEq/L | Pooled Placebo | 1.5g TRC101 BID | 3g TRC101 BID | 4.5g TRC101 BID |
|---|---|---|---|---|
| Change From Baseline to the End of Treatment (Day 15) in Serum Bicarbonate Within Each Individual TRC101 Dose Group | -0.2 ± 0.4 | 3.2 ± 0.4 | 3.0 ± 0.4 | 3.7 ± 0.4 |
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for each TRC101 dose group versus that for Placebo
| mEq/L | Pooled Placebo | 1.5g TRC101 BID | 3g TRC101 BID | 4.5g TRC101 BID |
|---|---|---|---|---|
| Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between Each TRC101 Dose Group Versus Placebo | -0.2 ± 0.4 | 3.2 ± 0.4 | 3.0 ± 0.4 | 3.7 ± 0.4 |
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline
| mEq/L | Combined TRC101 |
|---|---|
| Change From Baseline in Serum Bicarbonate at Day 15 Within the Combined TRC101 Treatment Group | 3.3 ± 0.2 |
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the Combined TRC101 Treatment Group versus that for Placebo
| mEq/L | Pooled Placebo | Combined TRC101 |
|---|---|---|
| Comparison of Change From Baseline in Serum Bicarbonate at Day 15 Between the Combined TRC101 Treatment Group Versus Placebo | -0.2 ± 0.4 | 3.3 ± 0.2 |
Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between each TRC101 BID Dose Group versus Placebo
| Participants | Pooled Placebo | 1.5g TRC101 BID | 3g TRC101 BID | 4.5g TRC101 BID |
|---|---|---|---|---|
| => 2 mEq/L Baseline Serum Bicarbonate | 4 | 18 | 14 | 19 |
| => 3 mEq/L Baseline Serum Bicarbonate | 2 | 14 | 10 | 16 |
| => 4 mEq/L Baseline Serum Bicarbonate | 1 | 8 | 10 | 11 |
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline
| mEq/L | 6g TRC101 QD |
|---|---|
| Change From Baseline in Serum Bicarbonate at Day 15 Within the TRC101 6g QD Dose Group | 3.5 ± 0.4 |
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g dose group versus that for Placebo
| mEq/L | Pooled Placebo | 6g TRC101 QD |
|---|---|---|
| Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus Placebo | -0.2 ± 0.4 | 3.5 ± 0.4 |
Serum bicarbonate at Day 15 minus serum bicarbonate at Baseline for the TRC101 6g QD dose group versus that for the TRC101 3g BID dose group
| mEq/L | 3g TRC101 BID | 6g TRC101 QD |
|---|---|---|
| Change From Baseline in Serum Bicarbonate at Day 15 Comparison Between the TRC101 6g QD Dose Group Versus the TRC101 3g BID Dose Group | 3.0 ± 0.4 | 3.5 ± 0.4 |
Comparison of the proportion of subjects whose serum bicarbonate values increased from Baseline to Day 15 by greater than or equal to 2, 3, or 4 mEq/L between the 6g TRC101 QD Dose Group versus Placebo
| Participants | Pooled Placebo | 6g TRC101 QD |
|---|---|---|
| => 2 mEq/L Baseline Serum Bicarbonate | 4 | 23 |
| => 3 mEq/L Baseline Serum Bicarbonate | 2 | 14 |
| => 4 mEq/L Baseline Serum Bicarbonate | 1 | 12 |
Collected over Through treatment period completion (Day 15). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pooled Placebo | 0/31 (0%) | 0/31 (0%) | 12/31 (38.7%) |
| 1.5g TRC101 BID | 0/25 (0%) | 0/25 (0%) | 13/25 (52%) |
| 3g TRC101 BID | 0/25 (0%) | 0/25 (0%) | 9/25 (36%) |
| 4.5g TRC101 BID | 0/26 (0%) | 0/26 (0%) | 17/26 (65.4%) |
| 6g TRC101 QD | 0/28 (0%) | 0/28 (0%) | 13/28 (46.4%) |
| Event | Pooled Placebo | 1.5g TRC101 BID | 3g TRC101 BID | 4.5g TRC101 BID | 6g TRC101 QD |
|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/31 | 9/25 | 3/25 | 6/26 | 3/28 |
| HeadacheNervous system disorders | 1/31 | 4/25 | 1/25 | 2/26 | 1/28 |
| ConstipationGastrointestinal disorders | 0/31 | 1/25 | 1/25 | 2/26 | 3/28 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/31 | 0/25 | 2/25 | 2/26 | 3/28 |
| Glomerular filtration rate decreasedInvestigations | 2/31 | 2/25 | 1/25 | 1/26 | 0/28 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/31 | 2/25 | 1/25 | 2/26 | 0/28 |
| HypertensionVascular disorders | 1/31 | 1/25 | 0/25 | 2/26 | 2/28 |
| Blood glucose increasedInvestigations | 2/31 | 1/25 | 0/25 | 0/26 | 1/28 |
Intent-to-treat (ITT) population
| Age, Continuous(years) | Pooled Placebo | 1.5g TRC101 BID | 3g TRC101 BID | 4.5g TRC101 BID | 6g TRC101 QD | Total |
|---|---|---|---|---|---|---|
| Mean | 61 ± 12 | 58 ± 14 | 60 ± 13 | 61 ± 13 | 63 ± 11 | 60.3 ± 12.44 |
| Sex: Female, Male(Participants) | Pooled Placebo | 1.5g TRC101 BID | 3g TRC101 BID | 4.5g TRC101 BID | 6g TRC101 QD | Total |
|---|---|---|---|---|---|---|
| Female | 12 | 6 | 8 | 11 | 12 | 49 |
| Male | 19 | 19 | 17 | 15 | 16 | 86 |
| Diabetes(Participants) | Pooled Placebo | 1.5g TRC101 BID | 3g TRC101 BID | 4.5g TRC101 BID | 6g TRC101 QD | Total |
|---|---|---|---|---|---|---|
| Count of participants | 20 | 18 | 20 | 19 | 17 | 94 |
| Hypertension(Participants) | Pooled Placebo | 1.5g TRC101 BID | 3g TRC101 BID | 4.5g TRC101 BID | 6g TRC101 QD | Total |
|---|---|---|---|---|---|---|
| Count of participants | 30 | 24 | 23 | 23 | 26 | 126 |
| Heart Failure(Participants) | Pooled Placebo | 1.5g TRC101 BID | 3g TRC101 BID | 4.5g TRC101 BID | 6g TRC101 QD | Total |
|---|---|---|---|---|---|---|
| Count of participants | 7 | 5 | 7 | 5 | 5 | 29 |
| Serum Bicarbonate(mEq/L) | Pooled Placebo | 1.5g TRC101 BID | 3g TRC101 BID | 4.5g TRC101 BID | 6g TRC101 QD | Total |
|---|---|---|---|---|---|---|
| Mean | 17.6 ± 1.4 | 18.0 ± 1.0 | 17.8 ± 1.2 | 17.5 ± 1.3 | 17.7 ± 1.0 | 17.72 ± 1.197 |
| eGFR(mL/min/1.73m^2) | Pooled Placebo | 1.5g TRC101 BID | 3g TRC101 BID | 4.5g TRC101 BID | 6g TRC101 QD | Total |
|---|---|---|---|---|---|---|
| Mean | 34 ± 14 | 35 ± 13 | 40 ± 13 | 35 ± 13 | 31 ± 10 | 35.70 ± 12.419 |
Plan to share: No
Ran from Mar 2016 to primary completion in Nov 2016, 8 months.
Results were first posted in Jan 2020, 3 years 2 months after primary completion. A results delay was requested in Nov 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Veverimer
Tricida, Inc.